Company news

NovoCure Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novocure to Report Third Quarter 2024 Financial Results

September 30, 2024

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

September 8, 2024

Novocure Announces Planned CEO Transition

September 2, 2024

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

August 27, 2024

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

August 13, 2024

Novocure Reports Second Quarter 2024 Financial Results

July 24, 2024

Novocure to Report Second Quarter 2024 Financial Results

June 30, 2024

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

June 2, 2024

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

May 22, 2024

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 1, 2024

Novocure Reports First Quarter 2024 Financial Results

May 1, 2024

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

April 23, 2024

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

April 4, 2024

Novocure to Report First Quarter 2024 Financial Results

March 31, 2024

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 26, 2024

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

March 10, 2024

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

February 21, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

January 17, 2024

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

January 8, 2024

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

January 7, 2024

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

January 3, 2024

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

November 27, 2023

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

November 20, 2023

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

November 9, 2023

Novocure Reports Third Quarter 2023 Financial Results

October 25, 2023

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

October 14, 2023

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

October 11, 2023

Novocure to Report Third Quarter 2023 Financial Results

October 1, 2023

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

September 28, 2023

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

September 7, 2023

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

August 28, 2023

Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

August 27, 2023

Novocure Reports Second Quarter 2023 Financial Results

July 26, 2023

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

July 20, 2023

Novocure to Report Second Quarter 2023 Financial Results

July 2, 2023

LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

June 5, 2023

Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education

May 31, 2023

Novocure Reports First Quarter 2023 Financial Results

May 3, 2023

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2023

Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

April 13, 2023

Novocure to Report First Quarter 2023 Financial Results

April 2, 2023

Kristin Stafford Joins Novocure Board of Directors

March 28, 2023

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

March 15, 2023

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

February 28, 2023

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

February 28, 2023

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 22, 2023

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

February 22, 2023

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 14, 2023

Novocure Announces Organizational Changes to Prepare for Future Growth

January 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.